What patents cover Hyftor (topical sirolimus) and who owns them?
Hyftor is a topical formulation of sirolimus used to treat facial angiofibromas associated with tuberous sclerosis complex (TSC). Patent coverage for Hyftor would typically include drug- and formulation-related patents (covering the topical sirolimus composition and delivery), plus any method-of-use patents tied to treating TSC-related angiofibromas.
However, the exact Hyftor patent numbers, assignees, and dates depend on the jurisdiction (for example, U.S. vs. Europe) and the specific patent family. The provided information does not include any Hyftor patent references or ownership details, so I can’t name specific Hyftor patents or the assignees reliably.
When do Hyftor patents expire (and what could extend exclusivity)?
Patent expiry depends on:
- The individual patent’s filing and grant dates (which set the baseline patent term)
- Statutory adjustments/extensions in the relevant country
- Possible additional protections such as regulatory exclusivity and pediatric extensions (where applicable)
Without the specific patent list (or the country/jurisdiction), I can’t calculate Hyftor’s expiry timing.
How can you find the Hyftor patent list quickly?
To get the exact Hyftor patents (and expiry dates), the fastest routes are:
- The drug’s entry in major patent/regulatory databases for your country (for example, the FDA Orange Book in the U.S.)
- The manufacturer’s patent listings or intellectual property pages (if they publish them)
- Patent family search in global patent databases using keywords like “sirolimus,” “topical,” and “angiofibromas,” plus “Hyftor”
If you tell me the country you care about (U.S., UK/EU, etc.), I can narrow down which database to use and what to search for.
Are there challenges or generic/biosimilar competitors tied to Hyftor patents?
If there are generic or alternative products, companies typically challenge patents through patent frameworks available in each jurisdiction (for example, U.S. pathways related to FDA approvals often intersect with listed patents). Whether Hyftor has active litigation, challenges, or approvals by competitors depends on the specific patent(s) and the regulatory status of alternatives.
No Hyftor litigation or competitor information was provided here, so I can’t confirm current disputes or competitors.
What does “Hyftor patent” usually mean in search results?
People searching “Hyftor patent” often want one of these:
- The key patents protecting topical sirolimus
- Patent expiry date(s) and timeline for market entry by competitors
- Whether a different company can sell a competing topical sirolimus for TSC-related angiofibromas before patents expire
- The status of patent litigation or FDA-related patent listings
Quick clarification so I can answer precisely
Which jurisdiction are you asking about (U.S., EU/UK, or another country), and do you want:
1) specific patent numbers/owners, or
2) the earliest expected exclusivity/expiry date?